A Randomized Clinical Trial of an Inactivated Avian Influenza A (H7N7) Vaccine

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  Couch, Robert B ^a   Patel, Shital M ^a   Wade Bowers, Chianti L ^a   Niño, Diane ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AVIAN INFLUENZA VACCINE; HEMAGGLUTINATION INHIBITING ANTIBODY; INACTIVATED SUBUNIT INFLUENZA A (H7N7) VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY TRACT DISEASE; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ANXIETY DISORDER; ARTICLE; AVIAN INFLUENZA; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEARING; HERPES LABIALIS; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INFLUENZA VACCINATION; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; MALAISE; MALE; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN REDNESS; THROAT IRRITATION; VOMITING;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; ANTIBODY FORMATION; BIRDS; FEMALE; HUMANS; INFLUENZA A VIRUS, H7N7 SUBTYPE; INFLUENZA IN BIRDS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; VACCINES, INACTIVATED;

AVES; INFLUENZA A VIRUS;

EID: 84871135645     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049704     Document Type: Article

References (27)

1. Webster RG, Bean WJ, Gorman OW, Chambers TM, Kawaoka Y, (1992) Evolution and ecology of influenza A viruses. Microbiol Rev 56: 152-79.
2. Taubenberger JK, Reid AH, Lourens RM, Wang R, Jin G, et al. (2005) Characterization of the 1918 influenza virus polymerase genes. Nature 437: 889-93.
3. Yen HL, Webster RG, (2009) Pandemic influenza as a current threat. Curr Top Microbiol Immunol 333: 3-24.
4. Fouchier RA, Munster V, Wallensten A, Bestebroer TM, Herfst S, et al. (2005) Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J Virol 79: 2814-2822.
5. Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, et al. (2012) A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A 109: 4269-74.
6. Yuen KY, Chan PKS, Peiris M, Tsang DNC, Que TL, Shortridge KF, et al. (1998) Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus. Lancet 351: 467-471.
7. Hien TT, Liem NT, Dung NT, San LT, Mai PP, van Vinh Chau N, et al. (2004) Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350: 1179-88.
8. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A(H5N1) Virus (2008) Update on avian influenza A(H5N1) virus infection in humans. N Engl J Med 358: 261-273.
9. Fouchier RA, Schneeberger PM, Rozendaal FW, Brockman JM, Kemink SA, et al. (2004) Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc Natl Acad Sci USA 101: 1356-1361.
10. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, et al. (2004) Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet 363: 587-593.
11. Peiris M, Yuen KY, Leung CW, Chan KH, Lai RWM, et al. (1999) Human infection with influenza H9N2. Lancet 354: 916-917.
12. Butt KM, Smith GJD, Chen H, Zhang LJ, Leung YHC, et al. (2005) Human infection with an avian H9N2 influenza A virus in Hong Kong in 2003. J Clin Microbiol 43: 5760-5767.
13. Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, et al. (2008) Development of Eurasian H7N7/PR high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine 26: 1742-1750.
14. Wood JM, Schild GC, Newman RW, Seagroatt V, (1977) An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determination of inactivated whole virus and subunit vaccines. J Biol Stand 5: 237-247.
15. Williams MS, (1993) Single-radial-immunodiffusion as an in vitro potency assay for human inactivated viral vaccines. Vet Microbiol 37: 253-262.
16. Stephenson I, Wood JM, Nicholson KG, Charlett A, Zambon MC, (2004) Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103: 91-95.
17. Rowe T, Abernathy RA, Hu-Primmer J, Thompson WW, Lu X, et al. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37: 937-943.
18. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, et al. (2007) Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25: 7656-7663.
19. Belser JA, Bridges CB, Katz JM, Tumpey TM, (2009) Past, present, and possible future human infection with influenza virus A subtype H7. Emerg Infect Dis 15: 859-865.
20. Hirst M, Astell CR, Griffith M, Coughlin SM, Moksa M, et al. (2004) Novel avian influenza H7N3 strain outbreak, British Columbia. Emerg Infect Dis 10: 2192-95.
21. Tweed SA, Skowronski DM, David ST, Larder DA, Petri M, et al. (2004) Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis 10: 2196-2199.
22. Keitel WA, Atmar RL (2009) Vaccines or pandemic influenza: summary of recent clinical trials. In: Compans RW, Orenstein WA, editors. Vaccines for pandemic influenza. Berlin Heidelberg: Springer-Verlag; pp. 431-447.
23. Pappas C, Matsuoka Y, Swayne DE, Donis RO, (2007) Development and evaluation of an influenza virus subtype H7N2 vaccine candidate for pandemic preparedness. Clin Vaccine Immunol 14: 1425-32.
24. Itoh Y, Ozaki H, Ishigaki H, Sakoda Y, Nagata T, et al. (2010) Subcutaneous inoculation of a whole virus particle vaccine prepared from a non-pathogenic virus library induces protective immunity against H7N7 highly pathogenic avian influenza virus in cynomolgus macaques. Vaccine 28: 780-789.
25. Min JY, Vogel L, Matsuoka Y, Lu B, Swayne D, et al. (2010) A live attenuated H7N7 candidate vaccine virus induces neutralizing antibody that confers protection from challenge in mice, ferrets, and monkeys. J Virol 84: 11950-11960.
26. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, et al. (2009) A phase I clinical trial of a PER.C6® cell grown influenza H7 virus vaccine. Vaccine 27: 1889-1897.
27. Talaat KR, Karron RA, Callahan KA, Luke CJ, DiLorenzo SC, et al. (2009) A live attenuated H7N3 influenza virus vaccine is well-tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 27: 3744-3753.